Polymer drugs and polymeric drugs. IX. Synthesis and 5-fluorouracil release profiles of biodegradable polymeric prodrugs γ-poly(α-hydroxymethyl-5 -fluorouracil-glutamate)KISHIDA, A; GOTO, H; MURAKAMI, K et al.Journal of bioactive and compatible polymers. 1998, Vol 13, Num 3, pp 222-233, issn 0883-9115Article

Validation of 24-Hour Flucytosine MIC Determination by Comparison with 48-Hour Determination by the Clinical and Laboratory Standards Institute M27-A3 Broth Microdilution Reference MethodLOCKHART, Shawn R; BOLDEN, Carol B; IQBAL, Naureen et al.Journal of clinical microbiology (Print). 2011, Vol 49, Num 12, pp 4322-4325, issn 0095-1137, 4 p.Article

Biochemical Modulation: Its Pharmacological Basis and Clinical ApplicationsLOW CHENG HOCK.Oncology. 1997, Vol 54, issn 0030-2414, 42 p., SUP1Conference Proceedings

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?YEN-REVOLLO, Jane L; GOLDBERG, Richard M; MCLEOD, Howard L et al.Clinical cancer research. 2008, Vol 14, Num 1, pp 8-13, issn 1078-0432, 6 p.Article

Précision des préparations à base de cytostatiques : étude réalisée sur 3 unités centralisées de reconstitution = Precision of the cytotoxics preparations : study realized on 3 cytotoxics drug preparation unitGIRARD, F; MENAT, C; GUENFOUDI, M.-P et al.Journal de pharmacie clinique (Paris). 1999, Vol 18, Num 1, pp 62-63, issn 0291-1981Conference Paper

Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine unitsTANABE, Kazuhito; SUGIURA, Masaaki; ITO, Takeo et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 17, pp 5164-5168, issn 0968-0896, 5 p.Article

Toxicité sévère à la capécitabine liée à un déficit enzymatique en dihydropyrimidine déshydrogénase (DPD) = Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiencyCOURSIER, S; MARTELET, S; GUILLERMET, A et al.Gastroentérologie clinique et biologique. 2010, Vol 34, Num 3, pp 218-223, issn 0399-8320, 6 p.Article

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulationMILANO, G; FERRERO, J.-M; FRANCOIS, E et al.British journal of cancer. 2004, Vol 91, Num 4, pp 613-617, issn 0007-0920, 5 p.Article

Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-CaribbeansLACHKAR, Y; LEYLAND, M; BLOOM, P et al.British journal of ophthalmology. 1997, Vol 81, Num 7, pp 555-558, issn 0007-1161Article

Fluorodeoxyuridine affects the identification of metabolic responses to daf-2 status in Caenorhabditis elegansDAVIES, Sarah K; LEROI, Armand M; BUNDY, Jacob G et al.Mechanisms of ageing and development. 2012, Vol 133, Num 1, pp 46-49, issn 0047-6374, 4 p.Article

Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil survival analysisBROADWAY, David C; BLOOM, Philip A; BUNCE, Catey et al.Ophthalmology (Rochester, MN). 2004, Vol 111, Num 4, pp 665-673, issn 0161-6420, 9 p.Article

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatographyLOOS, W. J; DE BRUIJN, P; VAN ZUYLEN, L et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 735, Num 2, pp 293-297, issn 1387-2273Conference Paper

Réactions allergiques après perfusion de 5 fluoro-uracile = Allergy after fluorouracil infusionLENOIR, B; LAFAY, J. P; GROSSO, V et al.La Lettre du cancérologue (Boulogne). 1997, Vol 6, Num 1, issn 1165-113X, p. 21Article

A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving CapecitabineHENIN, E; YOU, B; TOD, M et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 4, pp 418-425, issn 0009-9236, 8 p.Article

Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylaseFISCHER, Jennifer A; MULLER-WEEKS, Susan; CARADONNA, Salvatore J et al.Cancer research (Baltimore). 2006, Vol 66, Num 17, pp 8829-8837, issn 0008-5472, 9 p.Article

Does intermittent pulse topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?EPSTEIN, E.Journal of the American Academy of Dermatology. 1998, Vol 38, Num 1, pp 77-80, issn 0190-9622Article

Tegafur-induced photosensitivity : evaluation of provocation by UVB irradiationUSUKI, A; FUNASAKA, Y; OKA, M et al.International journal of dermatology. 1997, Vol 36, Num 8, pp 604-606, issn 0011-9059Article

Inappropriate continuation of medication when patients are admitted acutely: the example of capecitabineBOOTH, J. A; BOOTH, C; CRAWFORD, S. Michael et al.Clinical medicine. 2011, Vol 11, Num 5, issn 1470-2118, p. 511Article

Phase IB Study of the mTOR Inhibitor Ridaforolimus With CapecitabinePEROTTI, Antonella; LOCATELLI, Alberta; ALBANELL, Joan et al.Journal of clinical oncology. 2010, Vol 28, Num 30, pp 4554-4561, issn 0732-183X, 8 p.Article

The use of FUdR can cause prolonged longevity in mutant nematodesAITLHADJ, Layla; STÜRZENBAUM, Stephen R.Mechanisms of ageing and development. 2010, Vol 131, Num 5, pp 364-365, issn 0047-6374, 2 p.Article

An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practiceREMAUD, Gaëlle; BOISDRON-CELLE, Michèle; HAMELINE, Catherine et al.Journal of chromatography. B. 2005, Vol 823, Num 2, pp 98-107, issn 1570-0232, 10 p.Article

Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and OxoOHUCHIDA, A; KOUCHI, Y; SATO, S et al.Journal of toxicological sciences. 1996, Vol 21, pp 675-689, issn 0388-1350, SUP3Article

Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?HELSBY, N. A; LO, W. Y; THOMPSON, P et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 2, pp 405-407, issn 0344-5704, 3 p.Article

Optimizing Chemotherapy Dose and Schedule by Norton-Simon Mathematical ModelingTRAINA, Tiffany A; DUGAN, Ute; HIGGINS, Brian et al.Breast disease. 2010, Vol 31, Num 1, pp 7-18, issn 0888-6008, 12 p.Article

Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapyFÜRSTENBERGER, Gregor; SCHMID, Peter; DUQUESNE, Ans et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 2, pp 347-348, issn 0344-5704, 2 p.Article